{"contentid": 487927, "importid": NaN, "name": "Jury still out on Inovio's HPV vaccine", "introduction": "Despite claiming success in a Phase III trial of human papillomavirus (HPV) candidate VGX-3100, shares in Inovio Pharmaceuticals fell 15% on Tuesday, as investors worried over the strength of the data.", "content": "<p>Despite claiming success in a Phase III trial of human papillomavirus (HPV) candidate VGX-3100, shares in Inovio Pharmaceuticals (Nasdaq: INO) fell 15% on Tuesday, as investors worried over the strength of the data.</p>\n<p>The Plymouth Meeting, USA-based company is developing the DNA-based vaccine for the treatment of three HPV-16-/18-related diseases &ndash; cervical dysplasia, vulvar dysplasia and anal dysplasia.</p>\n<p>Inovio said the trial met primary and secondary endpoints &ldquo;among all evaluable subjects.\"</p>\n<p>This means the firm excluded eight patients for whom endpoint data were not available, creating a modified intention to treat (mITT) population against which to judge the success of the trial.</p>\n<p>Statistical significance was not reached in the full intention to treat (ITT) population, which considers such patients as non-responders.</p>\n<p>The uncertainty will ramp up pressure on a sister study, REVEAL 2, to show the future potential of the candidate as a replacement for surgical intervention. That trial is currently still enrolling.</p>\n<p>The results do however represent an important proof-of-concept for the company&rsquo;s platform, raising hopes for continued success down the line.</p>\n<p>Inovio had previously been focused on cancer vaccines, but in 2019 pivoted away from oncology to focus on HPV-related conditions, citing an overly competitive commercial landscape.</p>\n<p>The company also slashed its workforce by more than a quarter at that time.</p>\n<h2>Biomarker development</h2>\n<p>Inovio has been working with Dutch molecular diagnostics company Qiagen (NYSE: QGEN) to develop an<em> in-vitro</em> diagnostic, based on RNA sequencing technology, to identify treatment candidates for VGX-3100.</p>\n<p>If the firm is successful in gaining regulatory approval for its approach, these efforts will likely be crucial to its level of impact, with analysts forecasting peak sales of up to $400 million.</p>\n<p>Chief executive Joseph Kim said: \"We expect VGX-3100, if approved, to be an important therapeutic option for those impacted by HPV-16-/18-related disease.&rdquo;</p>\n<p>There were no treatment-related serious adverse events in the trial, and most adverse events were self-resolving and were considered to be mild to moderate, consistent with earlier clinical trials.</p>", "date": "2021-03-03 11:31:00", "meta_title": NaN, "meta_keywords": "Inovio, trial, success, VGX-, data, candidate, vaccine, dysplasia, Jury, shares, Pharmaceuticals, Tuesday, investors, worried, strength, Phase, claiming", "meta_description": "Despite claiming success in a Phase III trial of HPV candidate VGX-3100, shares in Inovio Pharmaceuticals fell 15% on Tuesday, as investors worried over the str", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-03 11:31:31", "updated": "2021-03-03 12:06:05", "access": NaN, "url": "https://www.thepharmaletter.com/article/jury-still-out-on-inovio-s-hpv-vaccine", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "inovio-big-1.jpg", "image2id": "inovio-small-1.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Infectious diseases, Oncology, Vaccines", "topic_tag": "Drug Trial, Research", "geography_tag": "USA", "company_tag": "Inovio Pharmaceuticals", "drug_tag": "VGX-3100", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-03 11:31:00"}